Russell Investments Group Ltd. trimmed its holdings in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 84.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,980 shares of the specialty pharmaceutical company’s stock after selling 26,826 shares during the quarter. Russell Investments Group Ltd.’s holdings in Flexion Therapeutics were worth $101,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Asset Management One Co. Ltd. bought a new position in shares of Flexion Therapeutics during the 1st quarter worth approximately $319,000. American International Group Inc. grew its stake in shares of Flexion Therapeutics by 52.3% during the 1st quarter. American International Group Inc. now owns 16,212 shares of the specialty pharmaceutical company’s stock worth $436,000 after acquiring an additional 5,569 shares in the last quarter. Nicholas Investment Partners LP bought a new position in shares of Flexion Therapeutics during the 1st quarter worth approximately $476,000. Bank of America Corp DE grew its stake in shares of Flexion Therapeutics by 28.9% during the 1st quarter. Bank of America Corp DE now owns 20,839 shares of the specialty pharmaceutical company’s stock worth $560,000 after acquiring an additional 4,676 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Flexion Therapeutics by 79.0% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company’s stock worth $743,000 after acquiring an additional 12,181 shares in the last quarter. 82.75% of the stock is owned by institutional investors and hedge funds.

Flexion Therapeutics, Inc. (NASDAQ FLXN) traded up 1.21% during midday trading on Friday, hitting $24.18. The stock had a trading volume of 710,408 shares. The stock’s market cap is $771.46 million. The company has a 50-day moving average price of $23.38 and a 200-day moving average price of $22.10. Flexion Therapeutics, Inc. has a 52 week low of $15.93 and a 52 week high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Equities analysts expect that Flexion Therapeutics, Inc. will post ($3.71) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Russell Investments Group Ltd. Lowers Position in Flexion Therapeutics, Inc. (FLXN)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/russell-investments-group-ltd-lowers-position-in-flexion-therapeutics-inc-flxn/1599301.html.

In related news, insider Yamo Deniz acquired 1,375 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at approximately $127,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought a total of 5,375 shares of company stock worth $131,575 in the last ninety days. Insiders own 15.98% of the company’s stock.

Several research firms have recently commented on FLXN. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 price objective (up previously from $30.00) on shares of Flexion Therapeutics in a report on Wednesday, July 12th. Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a report on Friday, July 7th. Finally, Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.50.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.